Validation Cohort

Uses

How it works

Dosage & preparation

Where it comes from

Highlighted claims

• CRT response will be assessed at 6 months using outpatient and hospitalisation records. — Development and real-world cohort validation of a meta-analysis-derived simplified scoring model for cardiac resynchronisation therapy response: a study protocol
• Responders are defined as patients meeting at least one criterion: improved NYHA class, increased LVEF, or reduced left ventricular end-systolic volume. — Development and real-world cohort validation of a meta-analysis-derived simplified scoring model for cardiac resynchronisation therapy response: a study protocol
• The validation cohort will include patients undergoing CRT implantation at the First Affiliated Hospital of Xinjiang Medical University from January 2018 to October 2025. — Development and real-world cohort validation of a meta-analysis-derived simplified scoring model for cardiac resynchronisation therapy response: a study protocol
• The target validation sample size is 343 patients, based on 120 required non-response events and an assumed 35% non-response rate. — Development and real-world cohort validation of a meta-analysis-derived simplified scoring model for cardiac resynchronisation therapy response: a study protocol
• Eligible validation procedures include CRT pacemakers, CRT defibrillators, and ICD-to-CRT upgrades. — Development and real-world cohort validation of a meta-analysis-derived simplified scoring model for cardiac resynchronisation therapy response: a study protocol
• Validation cohort inclusion requires optimized guideline-directed medical therapy before CRT, NYHA class II-IV, QRS duration of at least 120 ms, LVEF of 35% or below, and adult age. — Development and real-world cohort validation of a meta-analysis-derived simplified scoring model for cardiac resynchronisation therapy response: a study protocol